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 2 
Abstract 26 
Background: Staphylococcus aureus-induced arthritis causes rapid joint destruction, 27 
often leading to disabling joint damage despite antibiotics. We have previously shown 28 
that IL-15 inhibition without antibiotics is beneficial in S. aureus-induced arthritis. 29 
We therefore hypothesized that inhibition of IL-15, in combination with antibiotics, 30 
might represent a useful therapy that would both reduce inflammation and joint 31 
destruction, but preserve the host’s ability to clear the infection.  32 
Methods: Female wildtype C57BL/6 mice were intravenously inoculated with the 33 
TSST-1-producing LS-1 strain of S. aureus with 0.8x10
8
 S. aureus LS-1/mouse. 34 
Three days later the treatment was started consisting of cloxacillin followed by 35 
flucloxacillin, together with either anti-IL-15 antibodies (aIL-15ab) or control 36 
antibodies. Outcomes included survival, weight change, bacterial clearance, and joint 37 
damage. 38 
Results: The addition of aIL-15ab to antibiotics in S. aureus-induced arthritis reduced 39 
synovitis and bone erosions compared to controls. The number of bone-resorbing 40 
osteoclasts in the joints was reduced, whereas cartilage destruction was not 41 
significantly altered. Importantly, the combination therapy did not adversely affect the 42 
clinical outcome of S. aureus-induced arthritis, such as survival, weight change or 43 
compromise the host’s ability to clear the infection.  44 
Conclusions: As the clinical outcome of S. aureus-induced arthritis was not affected, 45 
the addition of aIL-15ab to antibiotics ought to be safe. Taken together, the 46 
combination of aIL-15ab and antibiotics is a beneficial, but not optimal, treatment of 47 
S. aureus-induced arthritis as it reduces synovitis and bone erosions but has a limited 48 
effect on cartilage destruction. 49 
Key words: IL-15; S. aureus; arthritis; immunopathogenesis; osteoclasts; mice.   50 
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 3 
Introduction 51 
Septic arthritis, most often caused by Staphylococcus aureus, is a medical emergency 52 
that leads to a rapid destruction of the bone and cartilage within the joint, culminating 53 
in irreversible joint damage if not promptly treated. Antibiotics and supportive care 54 
remain the mainstay of treatment. However, there is a need for therapy improvement 55 
as more than half of the treated patients develop permanent joint damage and 56 
dysfunction, despite eradication of the bacteria, due to the overwhelming host 57 
immune response to the pathogen (1, 2).  58 
 59 
Synovial inflammation is closely related to articular bone destruction. Infiltrating 60 
leukocytes and resident cells within the joint produce mediators such as receptor 61 
activator of nuclear factor-B ligand (RANKL), macrophage colony-stimulating 62 
factor (M-CSF), and pro-inflammatory cytokines like IL-1 and TNF, which leads to 63 
enhanced differentiation of bone-resorbing osteoclasts that mediate bone resorption 64 
(3). Osteoclast differentiation has been suggested to occur within the inflamed joint 65 
where osteoclast precursors of the monocyte-lineage have migrated from the bone 66 
marrow into the secondary lymphoid organs and subsequently to the joints (4). The 67 
identity of the osteoclast precursor within the inflamed joint is unclear, but the 68 
Ly6C
high 
monocyte subset, sometimes referred to as inflammatory monocytes, is a 69 
candidate (5). Cartilage destruction in the inflamed joint is on the other hand mediated 70 
by the inflammation-triggered secretion of matrix-degrading enzymes such as 71 
metalloproteinases (6) and possibly also by the bacterium itself and its associated 72 
toxins (7).  73 
 74 
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 4 
IL-15 is a pro-inflammatory cytokine that has a wide variety of functions at the 75 
interface between innate and adaptive immunity and has been considered to play a 76 
role in the immunopathogenesis of many inflammatory, infectious and autoimmune 77 
diseases (8). It has an essential role in the differentiation, proliferation and activation 78 
of NK cells, as well as in the maintenance of peripheral memory CD8
+
 T cells (8), 79 
and is thus of importance during viral infections (9). IL-15 also enhances the 80 
phagocytic activity of macrophages and neutrophils, and inhibits neutrophil apoptosis 81 
(10, 11). Furthermore, IL-15 is important for cell recruitment to inflamed areas 82 
through induction of other pro-inflammatory cytokines and chemokines. For example, 83 
it stimulates human monocytes to produce MCP-1 and IL-8, chemokines that recruit 84 
monocytes and neutrophils, respectively, to the site of inflammation (11).  85 
 86 
IL-15 has been implicated as a pro-osteoclastogenic cytokine (12-14) as it potentiates 87 
the in vitro differentiation of osteoclasts (12, 13). In addition, IL-15-activated NK 88 
cells from synovial fluid obtained from patients with rheumatoid arthritis could 89 
efficiently induce the formation of osteoclasts from monocytes (15). These NK cells 90 
expressed M-CSF and RANKL which were further up-regulated by IL-15. In patients 91 
with rheumatoid arthritis, IL-15 is detected at high concentrations in synovial fluid 92 
(16) and genetic variants of IL-15 associate with progression of joint destruction in 93 
Caucasian (17) but not Japanese patients (18). Thus, IL-15 may mediate bone 94 
resorption during inflammatory conditions. 95 
 96 
Serum protein levels of IL-15 increase during experimental S. aureus–induced 97 
arthritis and sepsis (19) and we have previously shown that both IL-15 knockout mice 98 
and mice treated with a monotherapy of anti-IL-15 antibodies (aIL-15ab), developed a 99 
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 5 
less destructive S. aureus-induced arthritis, compared with control groups (19). 100 
Furthermore, in other mouse models of aseptic arthritis, as well as in Gram-negative 101 
and endotoxin-induced murine sepsis, inhibition of IL-15 has been beneficial both 102 
with respect to arthritis development (20, 21) and survival during sepsis (22, 23).  103 
 104 
As the host immune response, rather than the pathogen itself, is responsible for the 105 
residual joint dysfunction in S. aureus-induced arthritis, several attempts have been 106 
made to reduce the severity of the arthritis by targeting the immune response, without 107 
adversely affecting host defence mechanisms. Antibiotics have been combined with 108 
corticosteroids without convincing effects on joint destruction in the mouse model of 109 
S. aureus-induced arthritis (24) but with beneficial effects in children with septic 110 
arthritis (25). Antibiotics have also been combined with biologics such as TNF 111 
inhibitors and IL-1 receptor antagonist with limited success (26-28).  112 
 113 
A delicate balance must be maintained between the immune system’s ability to clear 114 
the infection and the risk of collateral damage mediated by an overwhelming immune 115 
response. We and others have previously shown that inhibition of IL-15 protects 116 
against sepsis (19, 22, 23), as well as against both septic and aseptic arthritis 117 
development (19-21). We therefore hypothesized that IL-15 might represent a 118 
beneficial treatment target to combine with antibiotics in the treatment of S. aureus-119 
induced arthritis. The aim of the present study was to investigate if the addition of 120 
anti-IL-15 antibodies to antibiotics could improve the outcome of S. aureus-induced 121 
arthritis compared to antibiotic treatment alone.  122 
 123 
  124 
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 6 
Results 125 
IL15 inhibition added to antibiotic treatment does not adversely affect the 126 
systemic infection and systemic bone loss in S. aureus-induced arthritis 127 
To evaluate the effect of a combination therapy of aIL-15ab with antibiotics on 128 
experimental S. aureus-induced arthritis, mice were intravenously inoculated with S. 129 
aureus and 3 days later the combination therapy consisting of antibiotics together 130 
with either aIL-15ab or control antibodies, was started (Fig. 1A). At day 3 after 131 
bacterial inoculation, bone and cartilage destruction is already evident and progresses 132 
thereafter (29). The rationale for starting treatment at day 3 is to mimic the treatment 133 
delay which is present in the clinical setting of septic arthritis. 134 
 135 
Inhibition of IL-15 combined with antibiotic treatment did not significantly affect the 136 
clinical severity (Fig. 1B) or frequency of arthritis (data not shown), bacterial 137 
clearance (Fig 1. C), weight loss (Fig. 1D) or mortality (Fig. 1E) during the infection, 138 
compared to antibiotics with control antibodies. However, the monotherapy of aIL-139 
15ab reduced bacterial clearance and, to a certain extent, also weight loss (19), but not 140 
at all to the same degree as when antibiotics was added (Fig. S1A-D). The groups in 141 
Fig. S1A-D without antibiotics are previously published (19). 142 
 143 
S. aureus-induced arthritis results in a prominent systemic bone resorption (30). To 144 
evaluate whether the combination therapy would influence this feature of the 145 
infection, pQCT was performed on femoral bones 12 days postinfection. Treatment 146 
with antibiotics and aIL-15ab did not significantly influence trabecular bone mineral 147 
density, cortical thickness, or density (Fig. 1F, and Fig. S2A and B). 148 
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 149 
Thus, the addition of aIL-15ab to antibiotic therapy did not improve or adversely 150 
affect the clinical outcome of S. aureus-induced arthritis. 151 
 152 
Inhibition of IL-15 with antibiotic treatment reduces synovitis and bone 153 
erosions, but not cartilage destruction in S. aureus-induced arthritis 154 
As the clinical evaluation of arthritis has a limited sensitivity, we performed 155 
histopathological evaluation of joints at day 12 postinfection. Mice treated with the 156 
combination therapy of antibiotics and aIL-15ab developed less severe synovitis, 157 
compared to control mice treated with antibiotics and control antibodies, which was 158 
consistent with the finding of reduced proportions of granulocytes in the synovium 159 
(Fig. 2A and E). There were no differences between the two treatment groups in the 160 
proportions of lymphocytes, CD19
+
 B cells, T cells, NK cells, or NKT cells in the 161 
synovium (Fig. S3). Importantly, mice that received the combination therapy of 162 
antibiotics and aIL-15ab had reduced bone erosions, compared to control mice treated 163 
with antibiotics and control antibodies (Fig. 2B). There was no significant difference 164 
between the two groups with respect to cartilage destruction (Fig. 2C). Antibiotic 165 
treatment alone significantly reduced synovitis and bone destruction irrespective of 166 
aIL-15ab treatment, however, the effect was enhanced by the addition of aIL-15 ab 167 
(Fig. S1E and F). The groups in Fig. S1E and F without antibiotics are previously 168 
published (19). 169 
Osteoclasts are the only cells that resorb bone and are hence responsible for bone 170 
destruction in the inflamed joint. To evaluate whether the reduced bone erosions in 171 
the combination therapy group was due to an effect on osteoclast number, we 172 
performed Cathepsin K staining of joint sections. Indeed, mice treated with antibiotics 173 
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 8 
and aIL-15ab had fewer osteoclasts in their knee joints, compared to controls (Fig. 174 
2D). 175 
  176 
To assess whether the combination therapy had an inhibitory effect on osteoclast 177 
numbers by interfering with the molecular triad of RANK, RANKL, and OPG 178 
(osteoprotegerin; a decoy receptor for RANKL), we measured their relative mRNA 179 
expression levels in synovia from the knee joints from day 12 postinfection. At this 180 
time point no differences were observed between the groups (Fig. S2C-E). 181 
 182 
Taken together, the addition of aIL-15ab to antibiotic treatment during S. aureus-183 
induced arthritis enhances the reduction of synovitis and bone erosions, but not the 184 
cartilage destruction. These findings coincide with a reduced number of granulocytes 185 
in the synovium and fewer osteoclasts in in the joint. 186 
 187 
The combination therapy of aIL-15ab and antibiotics increases the proportion of 188 
inflammatory monocytes in the draining lymph nodes and decreases serum levels 189 
of MCP-1  190 
The Ly6C
high 
inflammatory monocyte subset (Fig. 3A) represents the major cell 191 
population that differentiates into osteoclasts once recruited into arthritic joints (5). 192 
As there were significantly fewer osteoclasts in the knee joints of mice treated with 193 
antibiotics and aIL-15ab compared to the controls, we assessed whether the therapy 194 
had an impact on these osteoclast precursors in the draining lymph nodes of the knee. 195 
There was an increased proportion of inflammatory Ly6C
high
 monocytes in the 196 
draining lymph nodes of mice treated with antibiotics and aIL-15ab, compared to 197 
control mice (Fig. 3B). At the same time, there were no major differences in the 198 
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 9 
proportions of other cell subsets in the draining lymph nodes (Fig. S4 in the 199 
supplemental material). Lastly, no differences were obtained between the groups with 200 
respect to the proportions of CD11b
+
 cells, neutrophils, inflammatory monocytes, or 201 
in the absolute cell number in the bone marrow (Fig. S5 in the supplemental material). 202 
IL-15 has been shown to be important for monocyte recruitment to inflammatory sites 203 
as IL-15 stimulates monocytes to produce MCP-1, which leads to monocyte 204 
recruitment to inflamed areas (11). Indeed, we found that serum levels of MCP-1 205 
were reduced in mice treated with antibiotics and aIL-15ab, compared to control mice 206 
(Fig. 3C). 207 
 208 
Taken together, the combination therapy of antibiotics and aIL-15ab leads to an 209 
increased proportion of inflammatory monocytes in the draining lymph nodes and 210 
reduced serum levels of MCP-1, compared to control treated mice. This suggests that 211 
these cells are not recruited into the inflamed joint to subsequently differentiate to 212 
bone-eroding osteoclasts, explaining the reduced numbers of osteoclasts in the joint 213 
and diminished bone erosions during S. aureus-induced arthritis.  214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
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 10 
Discussion 224 
In this study, we have shown that the addition of aIL-15ab to antibiotics as a 225 
treatment of S. aureus-induced arthritis reduced synovitis and bone erosions, as well 226 
as the number of osteoclasts in the joints, without compromising the host’s ability to 227 
clear the infection. Thus, although IL-15 is a cytokine that is important for innate 228 
immune responses, that are protective in the case of staphylococcal infections, aIL-229 
15ab ought to be a safe addition to antibiotics. 230 
 231 
S. aureus-induced arthritis is characterized by a very severe and rapid joint 232 
destruction, that often leads to disabling joint damage despite antibiotics (1). In 233 
systemic infection with S. aureus, bacterial elimination and joint destruction are 234 
mediated by the activation of cells in the immune system, with a substantial release of 235 
pro-inflammatory proteins essential for elimination of the invading pathogen. The 236 
same immune response can, on the other hand, be harmful to the host. In fact, 237 
eliminating the bacteria is not sufficient to prevent the joint damage and moreover, 238 
antibiotic-killed bacteria can induce and maintain joint inflammation (31). Therefore, 239 
it is tempting to seek for therapeutic approaches that could tip the balance to a more 240 
favourable outcome where the destructive processes could be avoided without 241 
negatively influencing the protective host response in clearing the infection. Many 242 
agents have been investigated to obtain this goal. Pre-treatment with an IL-1R 243 
antagonist aggravated S. aureus-induced arthritis with a more pronounced bone 244 
destruction and synovitis, and higher mortality, compared to controls (26). Combining 245 
antibiotics and a TNF inhibitor attenuated the postinfectious sequelae in S. aureus-246 
induced arthritis when administered three days after the initiation of the infection 247 
(28). However, pre-treatment with a TNF inhibitor worsened the outcome of S. 248 
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 11 
aureus-induced arthritis compared to controls, with a 30-fold increase in bacterial 249 
load in the kidneys and a more pronounced weight loss (27). Therefore, it is desirable 250 
to pursue other immunomodulatory agents that have a lower potential to interfere with 251 
the protective immune response. Based on our results, IL-15 is a promising candidate. 252 
Indeed, in the case of sepsis, IL-15 inhibition is beneficial both in polymicrobial and 253 
endotoxin-induced sepsis (22, 23), although in the case of Gram-positive S. aureus-254 
induced sepsis, IL-15 knockout mice have similar survival rates to that of wildtype 255 
mice (19). Further along these lines, Su et al recently advocated for an IL-15 256 
antagonist as a therapeutic agent in Stevens-Johnson syndrome and toxic epidermal 257 
necrolysis, which are life-threatening immune-related adverse drug reactions 258 
mediated by cytotoxic T lymphocytes and NK cells where IL-15 has been shown to 259 
be elevated and correlated with the progression and fatality of these severe 260 
hypersensitivity reactions (32).  261 
 262 
Inflammatory processes, both acute and chronic, are often accompanied by bone loss, 263 
and inflammation itself is a trigger for the formation of osteoclasts, bone erosions, and 264 
in some cases, systemic bone loss (3). IL-15 plays a role in osteoclastogenesis which 265 
seems to be overall pro-osteoclastogenic (12-14), but the results are somewhat 266 
contradictory. While IL-15-activated NK cells from synovial fluid of rheumatoid 267 
arthritis patients efficiently induced osteoclast formation from autologous monocytes 268 
(15), IL-15-activated NK cells from healthy donors trigger osteoclast apoptosis, thus 269 
displaying an anti-osteoclastogenic effect (33). We, and others, have also observed an 270 
anti-osteoclastogenic effect of IL-15 in vitro (28, 34) (B. Bergmann, unpublished 271 
data). These contrasting findings could mean that IL-15 displays paradoxical roles in 272 
osteoclastogenesis depending on the physiology, presence of inflammation and the 273 
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 12 
inflammatory cytokine profile and therefore, the precise effects of IL-15 on 274 
osteoclastogenesis remain to be fully elucidated. 275 
 276 
We have both previously (19) and in the present study, shown that inhibition of IL-15 277 
reduces the number of osteoclasts in the joint and the subsequent bone destruction 278 
during S. aureus-induced arthritis. Ly6C
high
 monocytes comprise precursor cells that 279 
differentiate to osteoclasts once recruited into the inflamed joint (5). Mice receiving 280 
antibiotics and aIL-15ab had higher proportions of Ly6C
high
 inflammatory monocytes 281 
in their draining lymph nodes compared with the controls, and fewer osteoclasts in 282 
their arthritic joints. IL-15 has been shown to be important for monocyte recruitment 283 
to inflammatory sites as IL-15 stimulates monocytes to produce MCP-1, which leads 284 
to monocyte recruitment to inflamed areas (11). As serum levels of MCP-1 were 285 
reduced in mice receiving the combination therapy we believe that the neutralization 286 
of IL-15 leads to an impaired production of MCP-1, followed by reduced recruitment 287 
of inflammatory monocytes to the joint and thus, reduced differentiation into bone-288 
eroding osteoclasts within the joint resulting in reduced bone erosions.  289 
 290 
Synovitis was reduced in mice receiving the combination therapy and the proportion 291 
of granulocytes in the synovium was lower. IL-15 influences neutrophil recruitment 292 
to inflammatory sites by modulating chemokine activity and inhibits neutrophil 293 
apoptosis (10, 11). It is therefore not surprising that IL-15 inhibition reduces the 294 
proportion of granulocytes in the synovium of the arthritic joint. The question is 295 
whether the combination therapy leads to a fewer number of osteoclasts in the joint 296 
via an inhibitory effect on synovial inflammation, consequently leading to a reduced 297 
osteoclast differentiation, or whether the effect is more directly targeted to the bone 298 
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erosive process. There were no differences between the treatment groups in synovial 299 
mRNA levels of RANK, RANKL, or OPG at day 12 postinfection. This suggests that 300 
IL-15 does not interfere with this molecular triad at this time point. Importantly, the 301 
reduction of synovitis in mice treated with aIL-15ab and antibiotics was not 302 
accompanied by a significant reduction in cartilage destruction. Cartilage degradation 303 
is mediated by the inflammation-induced secretion of matrix-degrading enzymes, 304 
such as metalloproteinases (6). Notably, cartilage and bone destructive processes 305 
occur through distinct mechanisms since that in the absence of osteoclasts during 306 
arthritic conditions, the bone erosive process is arrested without affecting cartilage 307 
degradation or synovial inflammation (35, 36). This could indicate that the effect of 308 
IL-15 inhibition on bone erosion is directly mediated through reduced 309 
osteoclastogenesis in the joint or the reduced recruitment of osteoclast precursors to 310 
the joint.  311 
 312 
The antibiotic regime was chosen in order to mimic the clinical setting, where patients 313 
are started on iv antibiotics at diagnosis and continued until they are stabilized and 314 
later changed to oral antibiotics. However, one limitation of the study design is that 315 
oral antibiotic consumption of each individual mouse was not tracked. 316 
 317 
The irreversible nature of the joint damage in S. aureus-induced arthritis, despite 318 
antibiotics, spur a need for new therapeutic procedures. Inhibition of IL-15 and 319 
antibiotics synergize in reducing synovitis and joint destruction in S. aureus-induced 320 
septic arthritis, and despite the fact that the combination therapy does not significantly 321 
influence cartilage destruction, it comprises a possible novel and safe treatment 322 
option.  323 
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Material and methods 324 
Mice 325 
8 weeks old female wildtype C57BL/6 mice were obtained from Scanbur (Sollentuna, 326 
Sweden). Previous studies have shown that male and female mice respond similarly to 327 
S. aureus-induced arthritis (19). Mice were maintained under standard conditions of 328 
temperature and light, and fed laboratory chow and water ad libitum at the animal 329 
facility at the Department of Rheumatology and Inflammation Research at the 330 
University of Gothenburg, Sweden. The local Animal Research Ethics Committee, in 331 
accordance with national animal welfare legislation, approved all of the animal 332 
procedures (121213 353-2012; 110928 378-2011). 333 
Mouse model of systemic S. aureus–induced arthritis 334 
The TSST-1-producing LS-1 strain of S. aureus was used for infection (37). Female 335 
wildtype C57BL/6 mice were inoculated intravenously in the tail vein with 0.8x10
8
 S. 336 
aureus LS-1/mouse in a total volume of 200 μl PBS. To determine the number of 337 
bacteria injected, viable counts were performed. Each mouse was weighed and 338 
examined daily for assessment of its overall condition, clinical signs of arthritis, and 339 
for signs of systemic infection. During the course of the infection the mice were 340 
graded blindly for clinical arthritis as previously described (19).  341 
In cases of severe systemic infection, when a mouse was judged too ill to survive 342 
another 24 hours, it was culled and defined as dead due to sepsis. Blood, bone 343 
marrow, kidneys, limbs, draining lymph nodes of the knee, and synovial tissue from 344 
knee joints were obtained at 12 days postinfection for further analysis.  345 
Treatment with antibiotics and anti-IL-15 antibodies 346 
IL-15 neutralizing antibodies were kindly provided by Amgen. Treatment was started 347 
on day 3 after bacterial inoculation and consisted of anti-IL-15 antibodies (aIL-15ab; 348 
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Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA) with 349 
antibiotics for the combination therapy group, and isotype control antibodies (IgG2a; 350 
Amgen Inc.) with antibiotics for the control group. This experiment was repeated 351 
three times, in total n = 30+30 mice. In an additional experiment, there were four 352 
treatment groups (n = 10 in each group) which are described in Table 1. The 353 
antibodies (25 µg/mouse) were injected intraperitoneally at days 3, 6, and 10 after 354 
bacterial inoculation. Intraperitoneal injections of cloxacillin (7,5 mg/mouse) were 355 
given twice daily from day 3 and stopped at day 6, when flucloxacillin was added to 356 
the drinking water (70 mg/kg). The rationale for starting treatment at day 3 is to 357 
simulate the treatment delay which is present in the clinical setting of septic arthritis. 358 
We also chose the antibiotic regime in order to mimic the clinical setting, where 359 
patients are started on iv antibiotics at diagnosis and continued until they are 360 
stabilized with a subsequent change to oral antibiotics. The per oral antibiotic mixture 361 
was changed every 3
rd
 day and the treatment groups were mixed to avoid cage effect, 362 
i.e. that the cage microenvironment could influence the outcome irrespective of 363 
genotype (38).  364 
Bacterial clearance 365 
S. aureus homes to joints and kidneys and persists there and thus, bacterial load in the 366 
kidneys is an indirect measurement of bacterial clearance. Kidneys were aseptically 367 
dissected, kept on ice, homogenized, serially diluted in PBS, and spread on blood agar 368 
plates. After 24 hours of incubation at 37°C, the number of colony forming units 369 
(CFU) per kidney pair was determined.  370 
Histopathology of inflamed joints  371 
The degree of cartilage destruction was assessed using Safranin O, which staining 372 
intensity is directly proportional to the proteoglycan content in the cartilage (39). 373 
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 16 
Bone erosions were detected using Weigert’s hematoxylin Van Gieson procedure of 374 
differential staining of collagen and other connective tissue (40). Joints were fixated, 375 
decalcificated and paraffin embedded. Tissue sections from fore- and hind paws were 376 
cut, deparaffinized and stained with hematoxylin-eosin (Histolab Products AB, 377 
Gothenburg, Sweden) or Weigert’s Iron hematoxylin (Histolab Products AB, 378 
Gothenburg, Sweden) prior to Van Gieson staining or Safranin O staining (Sigma-379 
Aldrich AB, Stockholm, Sweden) with Fast Green counterstaining (40). All slides 380 
were coded and two blinded observers evaluated each slide. The specimens were 381 
evaluated with regard to inflammatory cell accumulation in synovial tissue 382 
(synovitis), cartilage destruction, and bone erosions. The degree of synovitis and 383 
destruction yielded a score from 0 to 3 in every joint concerning finger/toes, 384 
wrists/ankles, elbows, and knee. Occasionally, one paw was embedded in a way that 385 
made it impossible to evaluate, and therefore the total score/mouse is divided by the 386 
number of evaluated joints.  387 
Immunohistochemical osteoclast staining 388 
The number of osteoclasts in femur and tibia epiphyses was determined by staining 389 
for Cathepsin K, a proteolytic enzyme predominantly expressed in osteoclasts, as 390 
previously described (41). All slides were coded and the number of Cathepsin K 391 
stained, multinucleated osteoclasts per 0.1 mm
2 
was counted in the epiphysis. 392 
Gene expression analysis 393 
Synovial tissue was obtained from the knee joints and RNA isolated using RNeasy 394 
Mini Kit (QIAGEN), according to the manufacturer’s instructions. The RNA quality 395 
was analysed using an Experion Bioanalyzer on a Experion RNA StdSens chip (Bio-396 
Rad laboratories Inc., USA) prior to cDNA synthesis with High Capacity cDNA 397 
Reverse Transcription kit (Applied Biosystems). Expression of Rank, Rankl and Opg 398 
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 17 
was measured with GAPDH as a reference gene. All reactions were amplified using 399 
TaqMan Gene expression PCR Master Mix (Applied Biosystems) and analysed on a 400 
Viia7 system (Applied Biosystems). 401 
Flow cytometry 402 
Single cell suspensions were prepared from spleens, draining lymph nodes of the 403 
knee, bone marrow, and synovia and pre-incubated with Fc-block (BD Biosciences). 404 
The antibodies used are summarized in Supplementary Table 1. Analyses were 405 
performed on a FACSCanto II, equipped with FACSDiva software (BD Bioscience) 406 
and with the FlowJo software (Tree Star Inc.). The gating strategies were based on 407 
fluorochrome minus one setting, when needed. Briefly, inflammatory monocytes were 408 
defined as CD11b
+
 Lineage
–
 (cells gated out using a B220, CD4, CD8, and NK1.1 409 
FITC dump channel), Ly6C
high
 and Ly6G
– 
(42).  410 
Enzyme-linked immunosorbent assay  411 
Blood was collected at indicated time points after S. aureus inoculation and serum 412 
was stored at -20°C for further analysis. The serum was analysed for MCP-1 by 413 
DuoSet® enzyme-linked immunosorbent assay (ELISA) Development kit (mouse 414 
CCL2/JE/MCP-1 (DY479-05), R&D systems, Europe Ltd, Abingdon, UK) according 415 
to the manufacturer’s recommendations. The assay was run on Spectra Max 340PC 416 
(Molecular Devices, Sunnyvale, CA) and analysis performed using SoftMax Pro 5.2 417 
software (Molecular Devices, Sunnyvale, CA).  418 
pQCT and assessment of bone mineral density 419 
Femoral bones were fixed in formalin and subsequently placed in 70% ethanol and 420 
subjected to peripheral quantitative computed tomography (pQCT) scan with Stratec 421 
pQCT XCT Research M, software version 5.4 B (Norland, Fort Atkinson, WI) at a 422 
resolution of 70 m. Trabecular bone mineral density (BMD) was determined with a 423 
 o
n
 M
arch 13, 2018 by SW
ETS SUBSCRIPTIO
N SERVICE
http://iai.asm
.org/
D
ow
nloaded from
 
 18 
metaphyseal scan, performed at a distance from the growth plate corresponding to 3% 424 
of the length of the femur. The inner 45% of the area was defined as the trabecular 425 
bone compartment.  426 
Statistical Analysis 427 
Statistical analyses were performed using Prism (GraphPad Software). Comparison 428 
between groups was performed using Mann-Whitney U test. Kaplan-Meier survival 429 
plots were prepared and the log-rank test was used for comparison between the 430 
survival curves. P < 0.05 was considered statistically significant.  431 
 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
  448 
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Figure legends 618 
Figure 1. The addition of anti-IL-15 antibodies (aIL-15ab) to antibiotics does not 619 
adversely affect the clinical course of Staphylococcus aureus-induced arthritis.  620 
(A) Mice were intravenously inoculated with S. aureus LS-1 and treated 3 days later 621 
with aIL-15ab with antibiotics for the combination therapy group, and control 622 
antibodies with antibiotics for the control group. The antibodies were injected 623 
intraperitoneally at days 3, 6, and 10 postinfection. The severity of arthritis (B) was 624 
evaluated during the course of the infection. (C) Bacterial persistence in the kidneys 625 
at 12 days postinfection. (D) Weight change as percentage of initial weight. (E) 626 
Cumulative survival during the 12-day period. Data are representative of three 627 
separate experiments with n = 10 mice/treatment group. (F) Femur trabecular bone 628 
mineral density (BMD) in the metaphysical region was measured with pQCT. Values 629 
from two experiments were pooled with n = 10 mice/treatment group. In panels B and 630 
D, bars show the mean ± standard error of the mean (SEM). In panels C and F, data is 631 
shown as median, whiskers = min to max. Statistical differences were calculated 632 
using Mann-Whitney U test. Kaplan-Meier survival plots were prepared and the log-633 
rank test was used for comparison between the two survival curves. *p< 0.05 634 
compared with control group. A, antibiotics; ctrl ab, control antibodies; aIL-15ab, 635 
anti-IL-15 antibodies; CFU, colony-forming units. 636 
 637 
Figure 2. Antibiotics and IL-15 inhibition reduces synovitis, bone erosions, and 638 
osteoclasts numbers in the joint but does not influence cartilage destruction 639 
during Staphylococcus aureus-induced arthritis.  640 
(A-E) Effects of the adding aIL-15ab to antibiotics on joint inflammation, bone 641 
erosions and cartilage destruction, number of osteoclasts and the proportion of 642 
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granulocytes in the synovium. Shown are representative H&E-, Van Gieson-, Safranin 643 
O-, and Cathepsin K stained sections of inflamed joints on day 12 postinfection. The 644 
severity of joint inflammation, or synovitis, and joint destruction was evaluated by 645 
making a histological scoring of synovitis (A), bone erosions (B), proteoglycan loss in 646 
the articular cartilage (C), and by counting the number of osteoclasts (arrows) in the 647 
epiphyseal part of femur and tibia after Cathepsin K staining (D). (E) The proportion 648 
of granulocytes in the synovium. Data are representative of three separate 649 
experiments with n = 10 mice/treatment group. Horizontal bars in A-E show median 650 
values, whiskers = min to max. Statistical differences were calculated using Mann-651 
Whitney U test. **p<0.01 compared with control group. Bars = 100 m. A, 652 
antibiotics; ctrl ab, control antibodies; aIL-15ab, anti-IL-15 antibodies. 653 
 654 
Figure 3. The combination therapy of aIL-15ab and antibiotics increases the 655 
proportion of inflammatory monocytes in the draining lymph nodes of the knee 656 
joints during Staphylococcus aureus-induced arthritis.  657 
(A) Representative illustration of the flow cytometry gating strategy for the analysis 658 
of Ly6C
high
 inflammatory monocytes in the draining lymph nodes of the knee joints. 659 
Debris and doublets were excluded and cells were sub-gated on CD11b
+
 Lineage
-
 660 
cells (gated out using a B220, CD4, CD8, and NK1.1 FITC dump channel). The 661 
remaining CD11b
+
 Lineage
-
 cells were then gated based on Ly6C and Ly6G 662 
expression and inflammatory monocytes are defined as Ly6C
high
 and Ly6G
-
. (B) The 663 
proportion of inflammatory monocytes is higher in mice receiving aIL-15ab and 664 
antibiotics, compared to control mice, 12 days after initiation of S. aureus-induced 665 
arthritis. Shown is representative flow cytometry analysis of the inflammatory 666 
monocyte subset in both treatment groups. (C) Serum levels of MCP-1 at day 3, 6 and 667 
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14 after bacterial inoculation. Horizontal bars show median values, whiskers = min to 668 
max. Statistical differences were calculated using Mann-Whitney U test. *p< 0.05 669 
compared with control group; **p<0.01 compared with control group. Open circles: 670 
control antibody + antibiotic-treated mice; Solid circles, aIL-15ab + antibiotic-treated 671 
mice. A, antibiotics; ctrl ab, control antibodies; aIL-15ab, anti-IL-15 antibodies. 672 
 673 
Table 1: Study design  674 
Treatment 
combinations 
Group 1 Group 2 Group 3 Group 4 
Antibody or 
isotype control 
Isotype control 
antibody ip 
aIL-15ab ip 
Isotype control 
antibody ip 
aIL-15ab ip 
Antibiotics or 
control fluid 
PBS control ip 
day 3-6 
PBS control ip 
day 3-6 
Cloxacillin ip day 
3-6 followed by 
oral flucloxacillin 
in drinking water 
Cloxacillin ip day 
3-6 followed by 
oral flucloxacillin 
in drinking water 
 675 
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